ResearchIn-Press PreviewCardiologyTherapeutics Open Access | 10.1172/jci.insight.185961
1Department of Cardiovascular Medicine, Physiology and Biomedical Engineerin, Mayo Clinic Arizona, Scottsdale, United States of America
2Department of Pediatrics, Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, United States of America
Find articles by Qiu, H. in: JCI | PubMed | Google Scholar
1Department of Cardiovascular Medicine, Physiology and Biomedical Engineerin, Mayo Clinic Arizona, Scottsdale, United States of America
2Department of Pediatrics, Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, United States of America
Find articles by Li, F. in: JCI | PubMed | Google Scholar
1Department of Cardiovascular Medicine, Physiology and Biomedical Engineerin, Mayo Clinic Arizona, Scottsdale, United States of America
2Department of Pediatrics, Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, United States of America
Find articles by Prachyl, H. in: JCI | PubMed | Google Scholar
1Department of Cardiovascular Medicine, Physiology and Biomedical Engineerin, Mayo Clinic Arizona, Scottsdale, United States of America
2Department of Pediatrics, Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, United States of America
Find articles by Patino-Guerrero, A. in: JCI | PubMed | Google Scholar
1Department of Cardiovascular Medicine, Physiology and Biomedical Engineerin, Mayo Clinic Arizona, Scottsdale, United States of America
2Department of Pediatrics, Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, United States of America
Find articles by Rubart, M. in: JCI | PubMed | Google Scholar
1Department of Cardiovascular Medicine, Physiology and Biomedical Engineerin, Mayo Clinic Arizona, Scottsdale, United States of America
2Department of Pediatrics, Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, United States of America
Find articles by Zhu, W. in: JCI | PubMed | Google Scholar |
Published November 14, 2024 - More info
Acute atrial ischemia is a well-known cause of postoperative atrial fibrillation (POAF). However, mechanisms through which ischemia contributes to the development of POAF are not well understood. In this study, ex vivo Langendorff perfusion was used to induce acute ischemia and reperfusion in the heart in order to mimic POAF. Inducibility of atrial fibrillation (AF) was evaluated using programmed electrical stimulation and confirmed with open-atrium optical mapping. Compared to the control group without ischemia, 25 minutes of ischemia substantially increased the incidence of AF. The right atrium was more susceptible to AF than the left atrium. Administering insulin for 30 minutes before ischemia and during reperfusion with 25 minutes of ischemia greatly reduced the vulnerability to AF. However, insulin treatment during reperfusion only did not show substantial benefits against AF. Optical mapping studies showed that insulin mitigates ischemia-induced abnormal electrophysiology, including shortened action potential duration and effective refractory period, slowed conduction velocity, increased conduction heterogeneity, and altered calcium transients. In conclusion, insulin reduced the risk of acute ischemia/reperfusion-induced AF via improving the electrophysiology and calcium handling of atrial cardiomyocytes, which provides a potential therapy for POAF.